IXHL stock is currently trading at $1.60, and the bull's view is optimistic due to recent FDA approval for a Phase 2 trial of its psilocybin-assisted therapy for anxiety, which could unlock significant market potential. Additionally, the appointment of Lou Barbato as Chief Medical Officer strengthens its leadership in drug development. The $60M financing agreement further supports its clinical trials, enhancing its growth prospects.